Trial Profile
Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- 27 Sep 2021 Planned End Date changed from 31 Jul 2022 to 19 Aug 2023.
- 03 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2021 Planned End Date changed from 1 Jun 2022 to 31 Jul 2022.